Nature cancer · 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.
СтатьяРандомизированное исследованиеКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Emmett Louise, Swiha Mina, Papa Nathan, Subramaniam Shalini, Crumbaker Megan, Joshua Anthony M, Nguyen Andrew, Weickhardt Andrew, Lee Sze-Ting, Ng Siobhan, Francis Roslyn J, Goh Jeffrey C, Pattison David A, Pathmanandavel Sarennya, Hope Thomas, Ayati Narjess, Hofman Michael S, Sandhu Shahneen, Niu Claire, Martin Andrew J, Thomas Hayley, Stockler Martin R, Davis Ian D, Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group
Аннотация
Prostate-specific membrane antigen (PSMA) receptor expression alters with androgen blockade in metastatic castrate-resistant prostate cancer (mCRPC). We evaluated the frequency and significance of early PSMA-positron emission tomography (PET) standardized uptake value (SUV) mean change with enzalutamide ± 177Lu-PSMA-617. ENZA-p is a randomized trial. Participants had mCRPC and 68Ga-PSMA positive disease. Participants were randomized (1:1) to enzalutamide or enzalutamide + 177Lu-PSMA-617, undergoing 68Ga-PSMA-PET-computed tomography (CT) at baseline and day 15 of enzalutamide treatment. 68Ga-PSMA-PET-CT were quantified for SUV mean. The study evaluated early SUV mean change, and prostate-specific-antigen (PSA) progression-free survival (PSA-PFS), 50% PSA-decline and overall survival. We randomized 162 participants, of whom 154 of 160 (96%) treated participants had PSMA-PET at day 15. SUV mean increased in 105 of 154 (68%) participants. Median PSA-PFS with increasing SUV mean was 5.8 (95% confidence interval (CI) 4.0-8.7) versus 13.1 (95%CI 10.5-17.0) months for enzalutamide versus enzalutamide + 177Lu-PSMA-617 (hazard ratio (HR) 0.38, 95%CI 0.25-0.58; log-rank P < 0.001). With decreasing SUV mean, median PSA-PFS was 12.5 (95%CI 3.2-23.6) versus 13.3 (95%CI 9.6-22.2) months for enzalutamide versus enzalutamide + 177Lu-PSMA-617 (HR 0.80, 95%CI 0.42-1.53; log-rank P = 0.5). The interaction between SUV mean increase or decrease and treatment arm for PSA-PFS was P = 0.055. Early PSMA-SUV mean increase is frequent, predicting shorter PSA-PFS with first-line enzalutamide in mCRPC. The addition of 177Lu-PSMA-617 to enzalutamide mitigated the short PSA-PFS in those with early PSMA SUV mean increase. ClinicalTrials.gov registration: NCT04419402 .